In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

GlycoMimetics, Inc.. Trade Record

NASDAQ:GLYC GlycoMimetics, Inc. stock gains 13.77% Exit Oct 2, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart GLYC Sep 15, 2017, priceSeries
About GlycoMimetics, Inc.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

Trade Information
Trade Type
LONG
ReliabilityScore™
93.33
Entry Date
Sep 15, 2017
Entry Price
11.82
Sell Date
Oct 2, 2017
Sell Price
13.45
Net Gain
13.77%
Hold Time
11 Trading Days